Hanmi Pharmaceutical announced on the 13th that Efinopegdutide, a new drug candidate for non-alcoholic steatohepatitis (NASH), has been designated as fast-track by the US Food and Drug Administration (FDA). Efinopegdutide is a dual agonist that simultaneously activates the GLP-1 receptor, which helps the secretion of insulin and suppresses appetite, and the glucagon receptor, which increases energy metabolism. The technology was transferred to MSD in August 2020. This fast-track designation was led by MSD.

Fast Track is a system to expedite the screening of new drug candidates being developed targeting diseases with high unmet medical demand due to lack of treatment. Phase 2a clinical trial of Efinopegd